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Objective. To augment the understanding of parvovirus B19 infection in pregnancy with respect to maternal characteristics and
their corresponding fetal outcomes. Study Design.R e t r o s p e c t i v ec a s e - s e r i e so fa l lw o m e nr e f e r r e dt oM a g e e - W o m e ns Hospital
with serologically-documented parvovirus B19 infection during pregnancy from 1998–2001. Results. All 25 cases that are available
for analysis occurred from January through June. The frequency of cases varied substantially from year to year, with 14 cases in
1998, 0 cases in 1999 and 2000, and 11 cases in 2001. In contrast to previous reports, the minority of women [4/25(16%)] ex-
perienced symptoms attributable to parvovirus B-19 infection although 3 of 25 (12%) fetuses developed hydrops fetalis and 4/25
(16%) suﬀered an intrauterine of fetal death. Conclusions. These ﬁndings suggest that parvovirus B19 infection in pregnancy fol-
lows seasonal and annual trend variation, may produce a lower frequency of maternal symptoms and a higher fetal loss rate than
previously reported. Synopsis. Maternal parvovirus B19 infection follows seasonal and annual variation is often asymptomatic and
may have higher fetal loss rates than previously reported. Continued surveillance is warranted.
Copyright © 2008 Richard H. Beigi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Parvovirus B19 is a small, nonenveloped DNA virus that
exclusively infects humans. After infection, parvovirus B19
replication occurs primarily in erythrocytes and erythrob-
lasts which can lead to anemia in predisposed individuals.
Children who are infected with parvovirus B19 typically de-
velop erythema infectiosum (ﬁfth disease) which is charac-
terized by a “slapped-cheek” rash, low-grade fever, and mild
inﬂuenza-like symptoms [1]. Infected healthy adults gener-
ally have mild constitutional symptoms only. In contrast,
immune-compromised individuals including fetuses can de-
velop severe chronic anemia requiring directed therapies [1].
Transmission occurs via respiratory secretions, and typically
occurs in outbreak fashion in the spring in childcare facil-
ities or schools, although outbreaks may occur sporadically
year-round.
Infection transmitted in utero from a susceptible mother
to the immune-incompetent fetus is recognized as an infre-
quent cause of fetal morbidity and mortality. Risk factors
for maternal infection have been described in a Danish pop-
ulation, and include large number of children in the house-
hold and occupational exposure (such as teacher or day-care
worker) [2, 3]. Although adult disease is generally mild, fetal
parvovirus B19 infection can cause spontaneous abortion in
theearlypartofpregnancyandaplasticanemia,nonimmune
hydrops fetalis and in utero fetal demise [4].
The exact frequency of these negative outcomes in utero
is unclear and there currently is no uniform consensus in the
obstetrical community as to the indications for conservative
versus aggressive management of maternal parvovirus B-19
infection [5]. The largest cohort of 618 parvovirus-exposed
pregnant women described by Harger et al. has suggested
that perinatal morbidity and mortality is rare among preg-
nancies complicatedbyparvovirus B19infection[6]. Among
52documentedmaternalseroconversions,theyreportedthat
there were no cases of nonimmune hydrops fetalis or fetal
death. In addition, the majority of these women had symp-
toms attributable to parvovirus infection, making clinical
identiﬁcation easier.2 Infectious Diseases in Obstetrics and Gynecology
We describe a more recent series of women from the
same institution to highlight alternative clinical ﬁndings and
higher rates of severe fetal outcomes from previous reports,
highlighting the need for continued surveillance of this po-
tentially devastating infectious disease in pregnancy.
2. MATERIAL AND METHODS
T h i sw a sar e t r o s p e c t i v ec a s e - s e r i e so fa l lg r a v i dw o m e nr e -
ferred to our hospital for possible parvovirus B19 exposure
between 1998 and 2001. Magee-Women’s is a large tertiary-
care maternity hospital that serves as a referral center for
the entire western Pennsylvania, eastern Ohio and northern
WestVirginia region.ThisstudywasapprovedbytheMagee-
Women’s Hospital institutional review board.
Demographic, medical, occupational, and outcome in-
formation from pregnant women referred to the Maternal-
Fetal Medicine Division at Magee-Women’s Hospital for
evaluation of possible exposure to parvovirus B19 (as well
as speciﬁc information regarding the nature of the exposure)
wascollectedusingastandardizedquestionnaire. Otherclin-
ical and obstetric outcome information was obtained us-
ing a computerized perinatal database maintained at our
institution. All patients with suspected exposure to par-
vovirus B19 had serial antibody titers to parvovirus B19
drawn to verify infection and were followed with the pro-
tocol outlined in Figure 1.F o rw o m e nw i t hd o c u m e n t e d
maternal infection (seroconversion of IgM), the fetus un-
derwent serial ultrasound evaluation weekly, and a cordo-
centesis was oﬀered when the ultrasound demonstrated ev-
idence of fetal hydrops or if the middle cerebral artery
peak systolic velocity values suggested severe anemia (mid-
dle cerebral artery peak systolic velocity, >1.50 multi-
ples of the median) as per our divisional guidelines for
practice.
Categorical data were evaluated using descriptive statis-
tics with the assistance of Stata 7.0 for Windows (Stata Corp.,
C o l l e g eS t a t i o n ,T e x ,U S A )
3. RESULTS
There were 25 cases of serologically-documented parvovirus
B19 infection during pregnancy from 1998 through 2001.
There was clear seasonal variation in disease incidence, with
all cases occurring from January through June. The fre-
quency of cases demonstrated substantial yearly variation,
with 14 cases in 1998, 0 cases in 1999 and 2000, and 11 cases
in 2001. The median age of the women in our cohort was 33
years (range, 16–39) and the median number of children liv-
ing at home with the women was 2 (range, 0–4). The median
gestational age at the time of diagnosis of maternal serocon-
version among the women was 22 2/7 weeks (range 2–41). In
terms of clinical ﬁndings, 19 (76%) of the women presented
for evaluation because they had a child at home with symp-
toms of pediatric parvovirus infection and only 4 (16%) of
women were symptomatic (Table 1).
PregnancyoutcomesarealsodescribedinTable 1.Ofsig-
niﬁcance, hydrops fetalis, and intrauterine fetal demise oc-
curred in 12% and 16% of our cohort, respectively. Among
Table 1: Occupation and clinical characteristics of women.
Cohort N = 25
Occupation N(%)
Work at home 11 (44%)
Business/oﬃce 7 (28%)
Health care 6 (24%)
Student/teacher 1 (4%)
Clinical characteristics N(%)
Asymptomatic 21 (84%)
Polyarthralgia 2 (8%)
Rash 4 (16%)
Fever 1 (4%)
Pregnancy outcomes N(%)
No. of ultrasounds performed, median (range) 6 (0–20)
Hydrops fetalis 3 (12%)
IUFD (a), 4 (16%)
(a) IUFD = intrauterine fetal death.
the three fetuses noted to have hydrops fetalis, two were
concomitantly diagnosed with intrauterine fetal deaths. The
third case of hydrops was noted in a living fetus. Cordocen-
tesis and intrauterine blood transfusion was oﬀered to this
patient and she declined. On serial surveillance ultrasounds,
this fetus was noted to have recovery of hydrops over two
weeks with concomitant improvement of noninvasive assess-
ments of fetal anemia using middle cerebral artery Doppler
velocimetry.Amongthefourfetaldeaths,twoweretheafore-
mentioned cases with hydrops and two occurred without hy-
drops. Of these 4 fetal deaths, only 1 woman had symptoms
potentially attributable to parvovirus B-19 infection (rash).
The median gestational age at birth was 39weeks (range,
14–42weeks), median birth weight was 3449grams (range,
280–4210), and median Apgar scores were 8 and 9 at 1 and
5minutes, respectively.
4. DISCUSSION
This investigation found much higher frequencies of unto-
ward in utero eﬀects attributable to parvovirus B-19 infec-
tion than previously reported. We report a frequency of 12%
for hydrops fetalis and 16% for in utero fetal demise. Re-
ported frequencies from large studies and reviews in the lit-
erature for hydrops fetalis and fetal demise are much lower,
rangingfrom0–1.0%and0–6.0%, respectively(1,6).Wealso
foundsigniﬁcantseasonalvariationinratesofperinatalcom-
plicationsfromparvovirusB-19infection. Cliniciansshould
be aware of these ﬁndings and recognize that nonimmune
hydrops fetalis or fetal demise is a real possibility and ap-
pears to ﬂuctuate based on seasonal and potential virulence
factors.
Our data support the notion that maternal symptoms
in the setting of parvovirus B19 infection during pregnancy
are uncommon. This is in contrast to Harger’s series in that
the majority of those women (67.0%) had symptoms at-
tributabletoparvovirusB-19infection,andthussoughtcare.
The majority of the women in our cohort presented dueRichard H. Beigi et al. 3
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Figure 1: Diagnostic and therapeutic protocol for evaluation of possible parvovirus B19 exposure in pregnancy.
to a child at home with symptoms of parvovirus infection.
This highlights the importance of educating women about
the nature of parvovirus infection in the pediatric setting. It
is critical to note that the prenatal care provider should test
any potentially exposed pregnant woman for parvovirus in-
fection even if she is asymptomatic, given the relatively low
frequency of symptoms among women who acquired infec-
tion in this cohort. Moreover, only 1 of 4 infected women
who later suﬀered a fetal demise reported symptoms, high-
lighting the lack of correlation between maternal symptoms
and untoward fetal outcomes.
RecentdatasupporttheassociationofparvovirusB19in-
fection in pregnancy with nonhydropic fetal death in the sec-
ond and third trimesters [7]. Ascertainment of our cohort
was contingent upon the patient presenting for care after re-
ferral based on a suspected exposure or (more rarely) symp-
toms of infection. In fact, the reproductive burden of par-
vovirus B19 infection during pregnancy may be greater than
our estimates in this report. This investigation does not in-
cludeanestimateofthecontributionofunrecognizedmater-
nal parvovirus B19 infection to spontaneous abortion, still-
birth, or other adverse pregnancy outcomes.
It is not readily apparent why fetal outcomes and the ma-
ternal symptom complex are diﬀerent in this report com-
pared with ﬁndings from the same institution over the previ-
ous eight years. No women in our cohort had medical prob-
lems placing them at risk for immune compromise. It is un-
clear if the diﬀerences in outcomes are mere statistical ﬂuc-
tuations or if there has been a change in the virulence of par-
vovirus B-19. Changing seasonal virulence patterns is a rec-
ognized phenomenon for other viral infections (inﬂuenza)
and is an equally viable explanation of our ﬁndings. It is also
possible that given our small sample size and the possibil-
ity of selection bias, our ﬁndings are not generalizable to the
obstetrical population at large and represent a small window
into the overall reproductive burden of parvovirus B-19 in-
fection.
When combining previous reports and the current re-
port the relationship between congenital parvovirus B19 in-
f e c t i o na n da d v e r s ep r e g n a n c yo u t c o m ei sc l e a r ,a n dm a yo c -
cur more commonly than previously reported. One strategy
that may be available in the future for prevention of disease
outbreaks is vaccination. A Phase I study of a recombinant
human parvovirus B19 vaccine suggests safety and immuno-
genicity among 24 subjects [8]. Certainly, such an interven-
tionisearlyinthedevelopmentphase,buthopefullywillpro-
vide us with a solution to a concerning problem. Until the
development of such a vaccine, however, we are obligated to
maintain vigilance for this serious pathogen and counsel our
patients appropriately with respect to both prevention and
management of this increasingly recognized and potentially
devastating congenital infectious disease.4 Infectious Diseases in Obstetrics and Gynecology
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